Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

OBJECTIVE: To investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 Fc fragment, in patients with generalized myasthenia gravis (gMG) with a history of anti-acetylcholine receptor (AChR) autoantibodies, who were on stable standard-of-care...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurology
Main Authors: Howard, James F., Bril, Vera, Burns, Ted M., Mantegazza, Renato, Bilinska, Malgorzata, Szczudlik, Andrzej, Beydoun, Said, Garrido, Francisco Javier Rodriguez De Rivera, Piehl, Fredrik, Rottoli, Mariarosa, Van Damme, Philip, Vu, Tuan, Evoli, Amelia, Freimer, Miriam, Mozaffar, Tahseen, Ward, E. Sally, Dreier, Torsten, Ulrichts, Peter, Verschueren, Katrien, Guglietta, Antonio, de Haard, Hans, Leupin, Nicolas, Verschuuren, Jan J.G.M.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6556100/
https://ncbi.nlm.nih.gov/pubmed/31118245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000007600
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados